Company news

iBio, Inc. news in 2022

iBio, Inc.'s news releases, calls and decks from 2022, newest first.

View company

iBio Announces Closing of $3.5 Million Underwritten Public Offering

December 8, 2022

iBio Announces Proposed Underwritten Public Offering

December 5, 2022

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

December 5, 2022

iBio Announces CEO Departure

December 1, 2022

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

September 26, 2022

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

September 20, 2022

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

August 15, 2022

iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer

May 8, 2022

iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants

May 1, 2022

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

February 13, 2022

iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease

January 25, 2022

Decks in 2022